{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:55:55Z","timestamp":1760316955041,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.schres.2023.03.008","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T17:28:29Z","timestamp":1679938109000},"page":"122-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An exploratory database study of factors influencing the continuation of brexpiprazole treatment (prescription) in patients with schizophrenia using information from psychiatric electronic medical records processed with natural language processing"],"prefix":"10.1016","volume":"255","author":[{"given":"Masaomi","family":"Iyo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Akiyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Shibasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Mamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2023.03.008_bb0005","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-244X-13-50","article-title":"The nature of relapse in schizophrenia","volume":"13","author":"Emsley","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2023.03.008_bb0010","first-page":"653","article-title":"Clinical application of artificial intelligence in psychiatry [in Japanese]","volume":"263","author":"Fujita","year":"2017","journal-title":"J. Clin. Exp. Med."},{"issue":"9","key":"10.1016\/j.schres.2023.03.008_bb0015","first-page":"1065","article-title":"Utilization of AI technology in psychiatric hospitals [in Japanese]","volume":"48","author":"Fujita","year":"2019","journal-title":"Jpn. J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.03.008_bb0020","first-page":"43","article-title":"Psychiatric pharmacotherapy using electronic medical record analysis solution [in Japanese]","volume":"24","author":"Fujita","year":"2021","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2023.03.008_bb0025","first-page":"455","article-title":"Clinical application of MENTAT\u00ae in psychiatry [in Japanese]","volume":"20","author":"Fujita","year":"2017","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2023.03.008_bb0030","first-page":"429","article-title":"Multidimensional analysis using MENTAT\u00ae electronic medical record analysis solution [in Japanese]","volume":"23","author":"Fujita","year":"2018","journal-title":"Jpn. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.03.008_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2021.102744","article-title":"Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project","volume":"63","author":"Hashimoto","year":"2021","journal-title":"Asian J. Psychiatr."},{"issue":"1","key":"10.1016\/j.schres.2023.03.008_bb0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.schres.2009.05.030","article-title":"Effectiveness of second-generation antipsychotics with acute-phase schizophrenia","volume":"113","author":"Hatta","year":"2009","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2023.03.008_bb0045","first-page":"259","article-title":"Clinically effective dose of brexiprazole rexulti: SDAM (serotonin-dopamine activity modulator) [in Japanese]","volume":"23","author":"Higuchi","year":"2018","journal-title":"Saishin Seishin Igaku"},{"issue":"5","key":"10.1016\/j.schres.2023.03.008_bb0050","first-page":"14","article-title":"Problem solving by analyzing psychiatric EMR, MENTAT\u00ae [in Japanese]","volume":"39","author":"Hirai","year":"2020","journal-title":"J. Jpn. Assoc. Psychiatr. Hosp."},{"issue":"3","key":"10.1016\/j.schres.2023.03.008_bb0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/npr2.12122","article-title":"Prescription patterns in patients with schizophrenia in Japan: first-quality indicator data from the survey of \u201cEffectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)\u201d project","volume":"40","author":"Ichihashi","year":"2020","journal-title":"Neuropsychopharmacol. Rep."},{"issue":"8","key":"10.1016\/j.schres.2023.03.008_bb0065","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/pcn.12275","article-title":"Psychotropic dose equivalence in Japan","volume":"69","author":"Inada","year":"2015","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.schres.2023.03.008_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2109","article-title":"Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia","volume":"11","author":"Inoue","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.schres.2023.03.008_bb0075","first-page":"1181","article-title":"Effectiveness of apiprazole in the treatment of schizophrenia for 18 months: focus on rates of treatment continuation, rehabilitation status, remission, and the discontinued group [in Japanese]","volume":"16","author":"Ishigaki","year":"2013","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.03.008_bb0080","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/npr2.12193","article-title":"Japanese Society of Neuropsychopharmacology: \u201cguideline for pharmacological therapy of schizophrenia\u201d","volume":"41","year":"2021","journal-title":"Neuropsychopharmacol. Rep."},{"issue":"6","key":"10.1016\/j.schres.2023.03.008_bb0085","first-page":"551","article-title":"Pharmacological properties of brexiprazole (serotonin-dopamine activity modulator; SDAM) [in Japanese]","volume":"22","author":"Kikuchi","year":"2019","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2023.03.008_bb0090","first-page":"135","article-title":"Large, automated administrative and clinical databases available for pharmacoepidemiology studies in Japan [in Japanese]","volume":"17","author":"Kimura","year":"2012","journal-title":"Jpn. J. Pharmacoepidemiol."},{"issue":"12","key":"10.1016\/j.schres.2023.03.008_bb0095","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2023.03.008_bb0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1741-7015-3-21","article-title":"Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs","volume":"3","author":"Liu-Seifert","year":"2005","journal-title":"BMC Med."},{"issue":"3","key":"10.1016\/j.schres.2023.03.008_bb0105","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2023.03.008_bb0115","first-page":"349","article-title":"A prescription survey of pharmacotherapy in Japanese inpatients with schizophrenia in 2011: from survey in 149 hospitals [in Japanese]","volume":"24","author":"Noda","year":"2015","journal-title":"Jpn. Bull. Soc. Psychiat."},{"issue":"1","key":"10.1016\/j.schres.2023.03.008_bb0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1744-859X-12-32","article-title":"Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review","volume":"12","author":"Olivares","year":"2013","journal-title":"Ann. General Psychiatry"},{"year":"2021","series-title":"Brexpiprazole [in Japanese]","key":"10.1016\/j.schres.2023.03.008_bb0130"},{"key":"10.1016\/j.schres.2023.03.008_bb0135","first-page":"1507","article-title":"Five-year observational study on aripiprazole use in outpatients with schizophrenia - a retrospective cohort investigation [in Japanese]","volume":"15","author":"Sumiyoshi","year":"2012","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2023.03.008_bb0140","first-page":"196","article-title":"Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice","volume":"70","author":"Taylor","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.03.008_bb0145","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.2147\/DDDT.S240859","article-title":"Brexpiprazole for the treatment of schizophrenia in adults: an overview of its clinical efficacy and safety and a psychiatrist\u2019s perspective","volume":"14","author":"Watanabe","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"10.1016\/j.schres.2023.03.008_bb0150","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/JCP.0000000000000385","article-title":"Effectiveness and predictors of continuation of paliperidone palmitate long-acting injection treatment: a 12-month naturalistic cohort study","volume":"35","author":"Whale","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2023.03.008_bb0155","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00228-020-03021-9","article-title":"An open-label, positron emission tomography study of the striatal D2\/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants","volume":"77","author":"Wong","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.03.008_bb0160","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/PPA.S26002","article-title":"Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan","volume":"5","author":"Ye","year":"2011","journal-title":"Patient Prefer. Adherence"},{"issue":"2","key":"10.1016\/j.schres.2023.03.008_bb0165","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/YIC.0000000000000296","article-title":"Association between previous high-dose antipsychotic therapy and brexpiprazole discontinuation after the initiation of brexpiprazole in patients with schizophrenia or schizoaffective disorder","volume":"35","author":"Yoshimura","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.03.008_bb0170","first-page":"1551","article-title":"Maintaining adherence by consistent self-medication: medication event monitoring system (MEMS) trial to evaluate the adherence of patients with schizophrenia in Japan [in Japanese]","volume":"14","author":"Zhao","year":"2011","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"issue":"2\u20133","key":"10.1016\/j.schres.2023.03.008_bb0175","article-title":"Maintaining favourable adherence by consistent self-administration of medication - medication event monitoring system (MEMS) trial to evaluate the compliance of patients with schizophrenia in Japan","volume":"117","author":"Zhao","year":"2010","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423001019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423001019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:52:53Z","timestamp":1760298773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423001019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":32,"alternative-id":["S0920996423001019"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.03.008","relation":{},"ISSN":["0920-9964"],"issn-type":[{"type":"print","value":"0920-9964"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An exploratory database study of factors influencing the continuation of brexpiprazole treatment (prescription) in patients with schizophrenia using information from psychiatric electronic medical records processed with natural language processing","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}